Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide
Overall mortality · people with systemic sclerosis
1 finding from 1 review
- no estimate extracted1 study · 19 participantsLow
Findings
What do systematic reviews say?
7 questions · 7 findings · 1 reviews
No studies found 3 · 42.9%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide
Event‐free survival · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide
Functional ability · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide
Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis
1 finding from 1 review
- no estimate extracted1 study · 19 participantsLow
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide
Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease. The study incorporated a ≥ 15% chance · people with systemic sclerosis
1 finding from 1 review
- no estimate extracted1 study · 19 participantsLow
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide
Pulmonary arterial hypertension · people with systemic sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide
Serious adverse events · people with systemic sclerosis
1 finding from 1 review
- no estimate extracted1 study · 19 participantsLow